T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy

Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma

(2020) Anusha Kalbasi et al.   Science Translational Medicine

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

(2019) Ana C. Garrido-Castro et al.   Cancer Discovery

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

(2019) Camilla Salvagno et al.   NATURE CELL BIOLOGY

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups

(2019) Oscar M. Rueda et al.   NATURE

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

(2019) Tina Gruosso et al.   JOURNAL OF CLINICAL INVESTIGATION

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer

(2019) Jaclyn Sceneay et al.   Cancer Discovery

The emerging role of epigenetic therapeutics in immuno-oncology

(2019) Michael J. Topper et al.   Nature Reviews Clinical Oncology

Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach

(2019) Yacine Bareche et al.   JNCI-Journal of the National Cancer Institute

Harnessing innate immunity in cancer therapy

(2019) Olivier Demaria et al.   NATURE

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy

(2018) Xudong Zhang et al.   ADVANCED MATERIALS

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

(2018) Tamara Maes et al.   CANCER CELL

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

(2018) Wanqiang Sheng et al.   CELL

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

(2018) Li Tang et al.   NATURE BIOTECHNOLOGY

Engineering PD-1-Presenting Platelets for Cancer Immunotherapy

(2018) Xudong Zhang et al.   NANO LETTERS

ERVmap analysis reveals genome-wide transcription of human endogenous retroviruses

(2018) Maria Tokuyama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

(2017) Chao Wang et al.   Nature Biomedical Engineering

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

(2016) Andy J. Minn et al.   CELL

IL-6 pathway in the liver: From physiopathology to therapy

(2016) Dirk Schmidt-Arras et al.   JOURNAL OF HEPATOLOGY

Anticancer Platelet-Mimicking Nanovehicles

(2015) Quanyin Hu et al.   ADVANCED MATERIALS

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

(2015) Giovanni Ciriello et al.   CELL

Nanoparticle biointerfacing by platelet membrane cloaking

(2015) Che-Ming J. Hu et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Genetic Engineering of Hematopoiesis for Targeted IFN-  Delivery Inhibits Breast Cancer Progression

(2014) G. Escobar et al.   Science Translational Medicine

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Nanoparticle-detained toxins for safe and effective vaccination

(2013) Che-Ming J. Hu et al.   Nature Nanotechnology

Impaired IFN-  Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

(2012) V. Sisirak et al.   CANCER RESEARCH

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

(2012) Bradley N Bidwell et al.   NATURE MEDICINE

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

(2011) C.-M. J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Annexin A1 regulates TGF-  signaling and promotes metastasis formation of basal-like breast cancer cells

(2010) M. de Graauw et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis

(2009) C. Domschke et al.   CANCER RESEARCH

Impaired interferon signaling is a common immune defect in human cancer

(2009) R. J. Critchley-Thorne et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis

(2008) Michele De Palma et al.   CANCER CELL

Nanoparticle-mediated cellular response is size-dependent

(2008) Wen Jiang et al.   Nature Nanotechnology